Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15–25 years

• Published in: Vaccine Vol. 27; no. 1; pp. 161 - 168
• Main Authors: Østergaard, Lars, Lebacq, Edouard, Poolman, Jan, Maechler, Gudrun, Boutriau, Dominique
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Ltd 01.01.2009; Elsevier; Elsevier Limited
• Subjects: Adolescent; Adolescents; Age; Allergy and Immunology; Antibodies, Bacterial - blood; Applied microbiology; Bacteriology; Biological and medical sciences; Epidemics; Female; Fundamental and applied biological sciences. Psychology; Health care; Humans; Immunogenicity; Male; Meningitis; Meningococcal Infections - prevention & control; Meningococcal Vaccines - administration & dosage; Meningococcal Vaccines - adverse effects; Meningococcal Vaccines - immunology; Meningococcal Vaccines - standards; Microbiology; Miscellaneous; Mortality; Neisseria meningitidis; Teenagers; Tetanus; Vaccines; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects); Vaccines, Conjugate - administration & dosage; Vaccines, Conjugate - adverse effects; Vaccines, Conjugate - immunology; Vaccines, Conjugate - standards; Young Adult; Young adults; Canada; Belgium; United States > US; Europe; Africa; Human; Toxicity; Toxoid; Neisseriaceae; Neisseria meningitidis; Vaccine; Infection; Immunogenicity; Adolescent; Bacteriosis; Bacteria; Micrococcales; Tetanus; Meningococcal disease
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2008.08.075

Development of meningococcal serogroups A, C, W-135 and Y conjugate vaccines could expand coverage against devastating meningococcal diseases. The immunogenicity of one dose of each one of five MenACWY-TT formulations versus a licensed ACWY polysaccharide vaccine was evaluated in 175 healthy subjects of 15–25 years. Serum bactericidal titers (rSBA) were evaluated before and after vaccination. The percentage of rSBA responders to each serogroup A, C, W-135 and Y did not statistically differ from the control for each of the five formulations except for serogroup A that was lower after administration of one formulation. In the 3-year follow-up of the first study where the latter formulation was assessed, bactericidal antibody persistence was similar to the licensed ACWY polysaccharide vaccine for MenA and MenC and higher for MenW-135 and MenY. Our results present five investigational MenACWY-TT conjugate vaccine formulations which are well tolerated and highly immunogenic in adolescents.